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Abstract
Progress in the treatment of acute respiratory distress syndrome
(ARDS) has been slow, perhaps in part due to the heterogeneity in
the biology underlying this syndrome. Open lung biopsy is a
feasible approach to define various subcategories of underlying
histology. In experienced hands, with careful selection of patients
and close attention to details of critical care management,
including mechanical ventilator settings, the procedure is safe even
in patients with severe disease. However, further work is needed to
define which patients, if any, experience a beneficial effect on
outcome from this procedure. More research is needed on
assessing efficacy of potential therapies within histologically
defined subgroups. In the future, various biomarkers may be
available to non-invasively classify ARDS patients from the
standpoint of responsiveness to various therapies, such as gluco-
corticoids.
In this issue of Critical Care, Kao and colleagues [1] consider
whether open lung biopsy (OLBx) can assist in the manage-
ment of patients with acute respiratory distress syndrome
(ARDS). Clinical outcome in ARDS remains poor despite
substantial advances in our understanding of the biology of
this syndrome [2]. Although limiting transpulmonary pressure
can clearly prevent worsening of ARDS, no other major
therapeutic advances with proven benefit have occurred in
this area [3]. Progress has been limited potentially due to the
heterogeneous phenotypes that are known to underlie the
American European Consensus definition of this disease.
Thus, methods to improve diagnostic specificity are likely to be
helpful in making progress.
OLBx has been used for years as a method of defining the
underlying pathology in patients with lung disease. While its
role has become established in the setting of interstitial lung
disease [4], its utility and safety are more controversial in
critically ill patients. Proponents of OLBx argue that
knowledge of underlying etiology can be helpful in defining
the best course of treatment [5]. In addition, the risk of biopsy
in experienced hands is fairly low if adequate precautions are
taken [6]. Opponents of OLBx cite the lack of specific
therapies for underlying etiologies of ARDS and believe that
defining the underlying mechanism of injury is largely
academic. A similar discussion has taken place in the
interstitial lung disease arena, where some advocate the
demonstration of usual interstitial pneumonitis among patients
with idiopathic pulmonary fibrosis, whereas others believe that
a therapeutic trial of steroids in the majority of patients is
justifiable until new therapeutic strategies emerge [4,7].
The work by Kao and colleagues [1] supports the existing
literature that open lung biopsy is fairly safe and frequently
revealing in the context of ARDS. There are several take
home points from this study. First, the authors corroborate
prior reports that the underlying pathology in clinical ARDS is
often a pattern other than diffuse alveolar damage or fibro-
proliferation. Of note, this and prior studies were retro-
spective analyses making the generalizability of these findings
difficult to define. Without knowing the total number of ARDS
cases potentially eligible for biopsy, we have no easy way to
know how common the observed abnormalities would be in
an unselected ARDS population.
Second, the authors found minimal morbidity attributable to
the surgical procedures that their patients underwent. These
data support the existing literature that, in experienced hands,
OLBx can be safely performed in carefully chosen patients.
The risk of bronchopleural fistula was fairly low in the present
study, which may reflect the use of protective mechanical
ventilation. We have recently observed that high pressures
measured at the airway opening are strongly predictive of
prolonged bronchopleural fistula risk following lung biopsy in
ARDS [8]. Thus, attention to mechanical ventilator settings
may be one factor that led to the low risk of this procedure.
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Third, the authors report that results from OLBx did indeed
affect clinical management. Nearly 75% of patients had
changes made in their therapeutic management due to
findings from OLBx. Whether these changes were helpful to
the patient is not entirely clear due to the lack of a control
group. However, at least 14 patients (11 with infections, 1
with hypersensitivity pneumonitis, and 2 with pulmonary edema)
had a disorder found for which accepted therapies exist.
Interestingly, the most common change in management
recorded in response to OLBx results was the institution of
glucocorticoid therapy. The role of glucocorticoid therapy in
ARDS has been controversial, with some smaller studies
showing benefits whereas other larger studies demonstrated
no important benefit [9,10]. A number of critiques have
emerged after the recently published New England Journal
of Medicine trial examining the role of steroids in persistent
ARDS [10], leading some to speculate that, despite the
negative results of that trial, some ARDS patients may still
benefit from anti-inflammatory therapy. In this recent study,
more than 95% of patients were excluded prior to enrollment,
leading to results that may not be generalizable to the overall
ARDS population. The most common reason for exclusion
was glucocorticoid therapy, yielding the possibility that the
best candidates for steroid therapy (from both an efficacy and
safety perspective) were excluded from the study. In addition,
the frequent use of paralytics (in up to 50% of steroid treated
participants) and marked hyperglycemia (mean values in
excess of 200 mg/dl) may have contributed to avoidable
complications of steroid therapy. Thus, the frequent re-
intubations and neuromyopathies that occurred in this recent
study may have offset the potential benefits of steroid
therapy. Regardless, the stratification of patients likely to
benefit from steroid therapy, while avoiding the potential
morbidity of pharmacological therapies and other intensive
care unit measures (including mechanical ventilation) is likely
to be a successful strategy. Future studies that aggressively
limit the side effects of steroids and that examine treatment
response stratified by OLBx findings may demonstrate
subgroups of patients that derive important benefit from this
therapy.
In the future, biomarkers that could be defined either in the
serum or by bronchoalveolar lavage would be preferable to
OLBx to stratify the likelihood of benefit from steroid therapy.
Such biomarkers may help define the underlying pathobiology
and so become a surrogate for OLBx in assessing the steroid
responsiveness of the disease. Another class of biomarkers
that may prove useful in the management of ARDS patients
would be ones that provided information on the intrinsic
steroid responsiveness of the patient [11,12]. The search for
genetic polymorphisms that predict individual responsiveness
to steroid therapies is well underway in other conditions such
as asthma and ulcerative colitis. Both types of biomarkers
would aid treatment decisions by better defining subgroups
most likely to benefit from steroid therapy. Thus, further work
is clearly needed to determine whether individualized therapy
will improve outcome in various subgroups of ARDS patients.
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